类风湿关节炎预防治疗的偏好:英国、德国和罗马尼亚的离散选择调查
该研究通过基于网络的离散选择实验调查了英国、德国和罗马尼亚共2959名成年人,假设其存在关节痛且未来2年发生类风湿关节炎(RA)的概率为60%,评估对预防治疗的偏好。结果显示多数参与者偏好治疗而非不治疗,最看重降低风险的治疗效果;对RA风险降低40%(从60%降至20%)的最大可接受风险分别为轻度副作用21.7%、严重感染19.1%、严重副作用2.2%。
要点
- 多数参与者偏好预防治疗而非不治疗,最重视治疗效果降低风险。
- 对RA风险降低40%的最大可接受风险:轻度副作用21.7%、严重感染19.1%、严重副作用2.2%。
- 五类别潜在类别模型拟合最佳,国家、感知RA风险、健康素养和计算能力预测类别归属。
核心结论
- 有效的RA预防性药物治疗为多数参与者所接受。
- 治疗属性的相对重要性和固定治疗方案的预期采纳率可由参与者特征预测。
研究设计与样本
- 通过调查面板在英国、德国和罗马尼亚招募成年人进行基于网络的调查,包含离散选择实验。
- 参与者假设存在关节痛且未来2年发生RA的概率为60%,完成15次选择(不治疗 vs 两种假设预防治疗)。
- 治疗由6个属性(有效性、风险和给药频率/途径)定义,属性水平可变。
- 参与者还完成了一项固定方案选择任务,反映候选预防治疗的主观估计。
- 采用潜在类别模型(LCM)分析,计算属性相对重要性、获益-风险权衡和预测治疗采纳率。
主要发现
- 共纳入2959名参与者的完整调查数据。
- 多数参与者偏好治疗而非不治疗,且对治疗效果降低风险的重视程度高于其他属性。
- 五类别LCM最佳拟合数据;国家、感知RA风险、健康素养和计算能力预测类别归属概率。
- 对RA风险降低40%(从60%降至20%)的最大可接受风险:轻度副作用21.7%、严重感染19.1%、严重副作用2.2%。
- 反映候选预防治疗的固定方案的预测采纳率在不同类别间存在差异。
关键数值与推荐
- 对RA风险降低40%(从60%降至20%)的最大可接受风险:轻度副作用21.7%、严重感染19.1%、严重副作用2.2%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To quantify preferences for preventive therapies for rheumatoid arthritis (RA) across three countries. METHODS: A web-based survey including a discrete choice experiment was administered to adults recruited via survey panels in the UK, Germany and Romania. Participants were asked to assume they were experiencing arthralgia and had a 60% chance of developing RA in the next 2 years and completed 15 choices between no treatment and two hypothetical preventive treatments. Treatments were defined by six attributes (effectiveness, risks and frequency/route of administration) with varying levels. Participants also completed a choice task with fixed profiles reflecting subjective estimates of candidate preventive treatments. Latent class models (LCMs) were conducted and the relative importance of attributes, benefit-risk trade-offs and predicted treatment uptake was subsequently calculated. RESULTS: Completed surveys from 2959 participants were included in the analysis. Most participants preferred treatment over no treatment and valued treatment effectiveness to reduce risk more than other attributes. A five-class LCM best fitted the data. Country, perceived risk of RA, health literacy and numeracy predicted class membership probability. Overall, the maximum acceptable risk for a 40% reduction in the chance of getting RA (60% to 20%) was 21.7%, 19.1% and 2.2% for mild side effects, serious infection and serious side effects, respectively. Predicted uptake of profiles reflecting candidate prevention therapies differed across classes. CONCLUSION: Effective preventive pharmacological treatments for RA were acceptable to most participants. The relative importance of treatment attributes and likely uptake of fixed treatment profiles were predicted by participant characteristics.
引用
- Simons G, Veldwijk J, DiSantostefano RL, et al. Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania. Rheumatology (Oxford). 2023. PMID: 36068022. doi:10.1093/rheumatology/keac397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。